CDKN2A and breast cancer: A distinguishing characteristic of vHMECs, p16INK4a promoter hypermethylation and subsequent silencing of protein expression, has been demonstrated in histologically normal mammary tissue from a substantial fraction of healthy, disease-free women with no predisposition to breast cancer [40].